{"transactions":[{"id":711739,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to buy)","published_at":"2026-07-09T20:54:03.000Z","date":"2026-07-08","kind":"exercise","planned":true,"acquired":true,"shares":32375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":6.38,"expiration_date":"2029-02-06","underlying":"Common Stock","underlying_shares":32375},"source":{"system":"sec-edgar","filing":"0001193125-26-299803","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000119312526299803/ownership.xml","form_type":"4"}},{"id":711738,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-09T20:54:03.000Z","date":"2026-07-08","kind":"sale","planned":true,"acquired":false,"shares":32375,"price":24.2402,"value":784776.475,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 1,564,551 options to purchase shares of common stock that are vested and immediately exercisable and a total of 813,949 options to purchase shares of common stock that have not yet vested."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale prices ranged from $24.00 to $24.43"}],"balance_after":484843,"source":{"system":"sec-edgar","filing":"0001193125-26-299803","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000119312526299803/ownership.xml","form_type":"4"}},{"id":711737,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-09T20:54:03.000Z","date":"2026-07-08","kind":"exercise","planned":true,"acquired":true,"shares":32375,"price":6.38,"value":206552.5,"ownership":{"direct":true},"balance_after":517218,"source":{"system":"sec-edgar","filing":"0001193125-26-299803","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000119312526299803/ownership.xml","form_type":"4"}},{"id":754217,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-06-02T20:30:02.000Z","date":"2026-06-01","kind":"sale","planned":false,"acquired":false,"shares":6847,"price":18.99,"value":130024.53,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units."}],"balance_after":484843,"source":{"system":"sec-edgar","filing":"0001193125-26-253601","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000119312526253601/ownership.xml","form_type":"4"}},{"id":828103,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-25T21:09:52.000Z","date":"2026-03-24","kind":"grant","planned":false,"acquired":true,"shares":45867,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":45867,"derivative":{"exercise_price":1.36,"expiration_date":"2036-03-24","underlying":"Common Stock","underlying_shares":45867},"source":{"system":"sec-edgar","filing":"0001193125-26-124342","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1507220/000119312526124342/ownership.xml","form_type":"4"}},{"id":911502,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-10T14:00:18.000Z","date":"2026-02-09","kind":"sale","planned":false,"acquired":false,"shares":17159,"price":21.028,"value":360819.452,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units."}],"balance_after":491690,"source":{"system":"sec-edgar","filing":"0001193125-26-043814","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000119312526043814/ownership.xml","form_type":"4"}},{"id":915824,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2026-02-06T22:54:06.000Z","date":"2026-02-04","kind":"grant","planned":false,"acquired":true,"shares":440000,"price":20.43,"value":8989200.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/48th of the shares subject to the option shall vest monthly over a four-year period."}],"balance_after":440000,"derivative":{"exercise_price":20.43,"expiration_date":"2036-02-04","underlying":"Common Stock","underlying_shares":440000},"source":{"system":"sec-edgar","filing":"0001193125-26-041500","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000119312526041500/ownership.xml","form_type":"4"}},{"id":915823,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-06T22:54:06.000Z","date":"2026-02-06","kind":"sale","planned":false,"acquired":false,"shares":7412,"price":20.62,"value":152835.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units."}],"balance_after":508849,"source":{"system":"sec-edgar","filing":"0001193125-26-041500","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000119312526041500/ownership.xml","form_type":"4"}},{"id":915822,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-06T22:54:06.000Z","date":"2026-02-04","kind":"grant","planned":false,"acquired":true,"shares":144600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Award of RSUs, representing the right to receive one share of Common Stock for each RSU. The number of shares of Common Stock acquired upon vesting of the RSUs is contingent upon the achievement of pre-established performance metrics, as approved by the Company's Compensation Committee, subject to the Reporting Person's continued service as an employee, consultant, director or officer of the Company."}],"balance_after":516261,"source":{"system":"sec-edgar","filing":"0001193125-26-041500","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000119312526041500/ownership.xml","form_type":"4"}},{"id":915821,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-06T22:54:06.000Z","date":"2026-02-04","kind":"grant","planned":false,"acquired":true,"shares":73000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of restricted stock units (\"RSUs\"), representing the right to receive one share of Common Stock for each RSU. One third (1/3rd) of the shares of Common Stock subject to such RSU shall vest annually on the anniversary of the Vesting Commencement Date, during the Reporting Person's continued service as an employee, consultant, director or officer of the Company over the three (3) years following the date of grant, until all of the shares subject to such RSU are fully vested."}],"balance_after":371661,"source":{"system":"sec-edgar","filing":"0001193125-26-041500","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000119312526041500/ownership.xml","form_type":"4"}},{"id":1045644,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock options (Right to buy)","published_at":"2025-09-08T22:45:31.000Z","date":"2025-09-08","kind":"exercise","planned":true,"acquired":true,"shares":157307,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":10.9,"expiration_date":"2025-09-09","underlying":"Common Stock","underlying_shares":157307},"source":{"system":"sec-edgar","filing":"0000950170-25-113659","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000095017025113659/ownership.xml","form_type":"4"}},{"id":1045643,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-09-08T22:45:31.000Z","date":"2025-09-08","kind":"sale","planned":true,"acquired":false,"shares":157307,"price":16.4139,"value":2582021.3673,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person solely covering equity grants with expiration dates prior to September 10, 2025. Following the sales reported in this Form 4, the Reporting Person has a total of 1,319,634 options to purchase shares of common stock that are vested and immediately exercisable and a total of 651,241 options to purchase shares of common stock that have not yet vested."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale prices ranged from $16.21 to $17.06."}],"balance_after":298661,"source":{"system":"sec-edgar","filing":"0000950170-25-113659","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000095017025113659/ownership.xml","form_type":"4"}},{"id":1045642,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-09-08T22:45:31.000Z","date":"2025-09-08","kind":"exercise","planned":true,"acquired":true,"shares":157307,"price":10.9,"value":1714646.3,"ownership":{"direct":true},"balance_after":455968,"source":{"system":"sec-edgar","filing":"0000950170-25-113659","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000095017025113659/ownership.xml","form_type":"4"}},{"id":1084565,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-07-18T20:30:04.000Z","date":"2025-07-16","kind":"sale","planned":false,"acquired":false,"shares":7534,"price":9.285,"value":69953.19,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units."}],"balance_after":298661,"source":{"system":"sec-edgar","filing":"0000950170-25-096947","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000095017025096947/ownership.xml","form_type":"4"}},{"id":1182731,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-02T13:05:43.000Z","date":"2025-03-31","kind":"grant","planned":false,"acquired":true,"shares":36979,"price":0.98,"value":36239.42,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":36979,"derivative":{"exercise_price":0.98,"expiration_date":"2035-03-31","underlying":"Common Stock","underlying_shares":36979},"source":{"system":"sec-edgar","filing":"0000950170-25-048903","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1507220/000095017025048903/ownership.xml","form_type":"4"}},{"id":1203416,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock options (Right to buy)","published_at":"2025-03-17T10:01:11.000Z","date":"2025-03-14","kind":"exercise","planned":false,"acquired":true,"shares":6074,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":7.2,"expiration_date":"2025-06-01","underlying":"Common Stock","underlying_shares":6074},"source":{"system":"sec-edgar","filing":"0000950170-25-039787","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000095017025039787/ownership.xml","form_type":"4"}},{"id":1203415,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-03-17T10:01:11.000Z","date":"2025-03-14","kind":"exercise","planned":false,"acquired":true,"shares":6074,"price":7.2,"value":43732.8,"ownership":{"direct":true},"balance_after":306195,"source":{"system":"sec-edgar","filing":"0000950170-25-039787","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000095017025039787/ownership.xml","form_type":"4"}},{"id":1219192,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock options (Right to buy)","published_at":"2025-03-06T21:10:30.000Z","date":"2025-03-04","kind":"exercise","planned":true,"acquired":true,"shares":7814,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":7.2,"expiration_date":"2025-06-01","underlying":"Common Stock","underlying_shares":7814},"source":{"system":"sec-edgar","filing":"0000950170-25-034634","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000095017025034634/ownership.xml","form_type":"4"}},{"id":1219191,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-03-06T21:10:30.000Z","date":"2025-03-04","kind":"sale","planned":true,"acquired":false,"shares":7814,"price":15.0453,"value":117563.9742,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person solely covering equity grants with expiration dates prior to September 10, 2025. Following the sales reported in this Form 4, the Reporting Person has a total of 1,321,245 options to purchase shares of common stock that are vested and immediately exercisable and a total of 805,428 options to purchase shares of common stock that have not yet vested."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale prices ranged from $15.00 to $15.27"}],"balance_after":300121,"source":{"system":"sec-edgar","filing":"0000950170-25-034634","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000095017025034634/ownership.xml","form_type":"4"}},{"id":1219190,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-03-06T21:10:30.000Z","date":"2025-03-04","kind":"exercise","planned":true,"acquired":true,"shares":7814,"price":7.2,"value":56260.8,"ownership":{"direct":true},"balance_after":307935,"source":{"system":"sec-edgar","filing":"0000950170-25-034634","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000095017025034634/ownership.xml","form_type":"4"}},{"id":1271219,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-02-12T22:15:20.000Z","date":"2025-02-10","kind":"sale","planned":false,"acquired":false,"shares":13288,"price":15.504,"value":206017.152,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units."}],"balance_after":300121,"source":{"system":"sec-edgar","filing":"0000950170-25-019000","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000095017025019000/ownership.xml","form_type":"4"}},{"id":1278484,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2025-02-07T21:42:46.000Z","date":"2025-02-05","kind":"grant","planned":false,"acquired":true,"shares":364000,"price":14.65,"value":5332600.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48th of the shares subject to the option shall vest monthly over a four-year period."}],"balance_after":364000,"derivative":{"exercise_price":14.65,"expiration_date":"2035-02-05","underlying":"Common Stock","underlying_shares":364000},"source":{"system":"sec-edgar","filing":"0000950170-25-016384","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000095017025016384/ownership.xml","form_type":"4"}},{"id":1278483,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-02-07T21:42:46.000Z","date":"2025-02-05","kind":"grant","planned":false,"acquired":true,"shares":89000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Award of RSUs, representing the right to receive one share of Common Stock for each RSU. The number of shares of Common Stock acquired upon vesting of the RSUs is contingent upon the achievement of pre-established performance metrics, as approved by the Company's Compensation Committee, subject to the Reporting Person's continued service as an employee, consultant, director or officer of the Company."}],"balance_after":313409,"source":{"system":"sec-edgar","filing":"0000950170-25-016384","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000095017025016384/ownership.xml","form_type":"4"}},{"id":1278482,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-02-07T21:42:46.000Z","date":"2025-02-05","kind":"grant","planned":false,"acquired":true,"shares":60500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of restricted stock units (\"RSUs\"), representing the right to receive one share of Common Stock for each RSU. One third (1/3rd) of the shares of Common Stock subject to such RSU shall vest annually on the anniversary of the Vesting Commencement Date, during the Reporting Person's continued service as an employee, consultant, director or officer of the Company over the three (3) years following the date of grant, until all of the shares subject to such RSU are fully vested."}],"balance_after":224409,"source":{"system":"sec-edgar","filing":"0000950170-25-016384","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000095017025016384/ownership.xml","form_type":"4"}},{"id":1484549,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-10T21:31:39.000Z","date":"2024-06-10","kind":"grant","planned":false,"acquired":true,"shares":70683,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in three equal annual installments beginning on the first anniversary of June 10, 2024, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":70683,"derivative":{"exercise_price":3.97,"expiration_date":"2034-06-10","underlying":"Common Stock","underlying_shares":70683},"source":{"system":"sec-edgar","filing":"0000950170-24-071438","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1507220/000095017024071438/ownership.xml","form_type":"4"}},{"id":1651298,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2024-02-09T21:05:03.000Z","date":"2024-02-07","kind":"grant","planned":false,"acquired":true,"shares":214500,"price":22.28,"value":4779060.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48th of the shares subject to the option shall vest monthly over a four-year period."}],"balance_after":214500,"derivative":{"exercise_price":22.28,"expiration_date":"2034-02-07","underlying":"Common Stock","underlying_shares":214500},"source":{"system":"sec-edgar","filing":"0001562180-24-001223","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218024001223/primarydocument.xml","form_type":"4"}},{"id":1651297,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-02-09T21:05:03.000Z","date":"2024-02-07","kind":"grant","planned":false,"acquired":true,"shares":39000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Award of RSUs, representing the right to receive one share of Common Stock for each RSU.  The number of shares of Common Stock acquired upon vesting of the RSUs is contingent upon the achievement of pre-established performance metrics, as approved by the Company's Compensation Committee, subject to the Reporting Person's continued service as an employee, consultant, director or officer of the Company."}],"balance_after":163909,"source":{"system":"sec-edgar","filing":"0001562180-24-001223","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218024001223/primarydocument.xml","form_type":"4"}},{"id":1651296,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-02-09T21:05:03.000Z","date":"2024-02-07","kind":"grant","planned":false,"acquired":true,"shares":107250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of restricted stock units (\"RSUs\"), representing the right to receive one share of Common Stock for each RSU.  One third (1/3rd) of the shares of Common Stock subject to such RSU shall vest annually on the anniversary of the Vesting Commencement Date, during the Reporting Person's continued service as an employee, consultant, director or officer of the Company over the three (3) years following the date of grant, until all of the shares subject to such RSU are fully vested."}],"balance_after":124909,"source":{"system":"sec-edgar","filing":"0001562180-24-001223","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218024001223/primarydocument.xml","form_type":"4"}},{"id":1844644,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-26T16:05:23.000Z","date":"2023-06-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":80000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) (\"Parent\"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the \"Effective Time\"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) (\"Parent\"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the \"Effective Time\"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) (\"Parent\"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the \"Effective Time\"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes)"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"(Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."}],"balance_after":0,"derivative":{"exercise_price":4.08,"underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0000899243-23-016486","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089924323016486/doc4.xml","form_type":"4"}},{"id":1844643,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-26T16:05:23.000Z","date":"2023-06-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":80000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) (\"Parent\"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the \"Effective Time\"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) (\"Parent\"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the \"Effective Time\"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) (\"Parent\"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the \"Effective Time\"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes)"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"(Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."}],"balance_after":0,"derivative":{"exercise_price":4.49,"underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0000899243-23-016486","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089924323016486/doc4.xml","form_type":"4"}},{"id":1844642,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-26T16:05:23.000Z","date":"2023-06-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":80000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) (\"Parent\"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the \"Effective Time\"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) (\"Parent\"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the \"Effective Time\"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) (\"Parent\"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the \"Effective Time\"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes)"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"(Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."}],"balance_after":0,"derivative":{"exercise_price":3.3,"underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0000899243-23-016486","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089924323016486/doc4.xml","form_type":"4"}},{"id":1844641,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-26T16:05:23.000Z","date":"2023-06-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":63000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) (\"Parent\"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the \"Effective Time\"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) (\"Parent\"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the \"Effective Time\"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) (\"Parent\"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the \"Effective Time\"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes)"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"(Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."}],"balance_after":0,"derivative":{"exercise_price":1,"underlying":"Common Stock","underlying_shares":63000},"source":{"system":"sec-edgar","filing":"0000899243-23-016486","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089924323016486/doc4.xml","form_type":"4"}},{"id":1844640,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-26T16:05:23.000Z","date":"2023-06-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":60000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) (\"Parent\"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the \"Effective Time\"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) (\"Parent\"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the \"Effective Time\"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) (\"Parent\"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the \"Effective Time\"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes)"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"(Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."}],"balance_after":0,"derivative":{"exercise_price":4.61,"underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0000899243-23-016486","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089924323016486/doc4.xml","form_type":"4"}},{"id":1844639,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-26T16:05:23.000Z","date":"2023-06-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) (\"Parent\"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the \"Effective Time\"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) (\"Parent\"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the \"Effective Time\"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) (\"Parent\"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the \"Effective Time\"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes)"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"(Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."}],"balance_after":0,"derivative":{"exercise_price":4.25,"underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-23-016486","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089924323016486/doc4.xml","form_type":"4"}},{"id":1923267,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-04-07T18:22:12.000Z","date":"2023-04-05","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option vests on the first to occur of (i) the date that is twelve months after the date of grant, and (ii) immediately prior to the first annual meeting of the Company's stockholders in 2024 at which one or more members of the Company's Board of Directors are to be elected, subject to the Reporting Person's continued service through such date or event."}],"balance_after":80000,"derivative":{"exercise_price":4.08,"expiration_date":"2033-04-05","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0000899243-23-010983","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089924323010983/doc4.xml","form_type":"4"}},{"id":2026246,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2023-02-08T21:49:37.000Z","date":"2023-02-06","kind":"exercise","acquired":false,"shares":5959,"price":27.6384,"value":164697.2256,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":6.38,"expiration_date":"2029-02-06","underlying":"Common Stock","underlying_shares":5959},"source":{"system":"sec-edgar","filing":"0001562180-23-001118","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218023001118/primarydocument.xml","form_type":"4"}},{"id":2026245,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-02-08T21:49:37.000Z","date":"2023-02-06","kind":"sale","acquired":false,"shares":5959,"price":27.6384,"value":164697.2256,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 735,987 options to purchase shares of common stock that are vested and immediately exercisable and a total of 809,583 options to purchase shares of common stock that have not yet vested."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale prices ranged from $27.50 to $27.84."}],"balance_after":17659,"source":{"system":"sec-edgar","filing":"0001562180-23-001118","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218023001118/primarydocument.xml","form_type":"4"}},{"id":2026244,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-02-08T21:49:37.000Z","date":"2023-02-06","kind":"exercise","acquired":true,"shares":5959,"price":6.38,"value":38018.42,"ownership":{"direct":true},"balance_after":23618,"source":{"system":"sec-edgar","filing":"0001562180-23-001118","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218023001118/primarydocument.xml","form_type":"4"}},{"id":2032323,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2023-02-03T22:02:17.000Z","date":"2023-02-02","kind":"grant","acquired":true,"shares":410000,"price":28.55,"value":11705500.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to the option shall vest monthly over a four-year period."}],"balance_after":410000,"derivative":{"exercise_price":28.55,"expiration_date":"2033-02-02","underlying":"Common Stock","underlying_shares":410000},"source":{"system":"sec-edgar","filing":"0001562180-23-000956","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218023000956/primarydocument.xml","form_type":"4"}},{"id":2120460,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-11-10T16:54:15.000Z","date":"2022-11-08","kind":"exercise","acquired":false,"shares":63000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares underlying the option were fully vested on March 11, 2021, the date that is twelve months after the date of grant."}],"balance_after":63000,"derivative":{"exercise_price":1,"expiration_date":"2030-03-11","underlying":"Common Stock","underlying_shares":63000},"source":{"system":"sec-edgar","filing":"0000891293-22-000055","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000055/primary_doc.xml","form_type":"4"}},{"id":2120459,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-11-10T16:54:15.000Z","date":"2022-11-08","kind":"exercise","acquired":false,"shares":28500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying the option were fully vested on May 16, 2020, the date that is twelve months after the date of grant."}],"balance_after":0,"derivative":{"exercise_price":0.8411,"expiration_date":"2029-05-16","underlying":"Common Stock","underlying_shares":28500},"source":{"system":"sec-edgar","filing":"0000891293-22-000055","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000055/primary_doc.xml","form_type":"4"}},{"id":2120458,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"common stock","published_at":"2022-11-10T16:54:15.000Z","date":"2022-11-08","kind":"sale","acquired":false,"shares":4500,"price":5.7022,"value":25659.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $ 5.70 to $ 5.72. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000891293-22-000055","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000055/primary_doc.xml","form_type":"4"}},{"id":2120457,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"common stock","published_at":"2022-11-10T16:54:15.000Z","date":"2022-11-08","kind":"sale","acquired":false,"shares":36942,"price":5.6461,"value":208578.2262,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $ 5.60 to $ 5.695. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."}],"balance_after":4500,"source":{"system":"sec-edgar","filing":"0000891293-22-000055","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000055/primary_doc.xml","form_type":"4"}},{"id":2120456,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"common stock","published_at":"2022-11-10T16:54:15.000Z","date":"2022-11-08","kind":"sale","acquired":false,"shares":50058,"price":5.5292,"value":276780.6936,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $ 5.50 to $ 5.59. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."}],"balance_after":41442,"source":{"system":"sec-edgar","filing":"0000891293-22-000055","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000055/primary_doc.xml","form_type":"4"}},{"id":2120455,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"common stock","published_at":"2022-11-10T16:54:15.000Z","date":"2022-11-08","kind":"exercise","acquired":true,"shares":63000,"price":1,"value":63000.0,"ownership":{"direct":true},"balance_after":91500,"source":{"system":"sec-edgar","filing":"0000891293-22-000055","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000055/primary_doc.xml","form_type":"4"}},{"id":2120454,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"common stock","published_at":"2022-11-10T16:54:15.000Z","date":"2022-11-08","kind":"exercise","acquired":true,"shares":28500,"price":0.8411,"value":23971.35,"ownership":{"direct":true},"balance_after":28500,"source":{"system":"sec-edgar","filing":"0000891293-22-000055","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000055/primary_doc.xml","form_type":"4"}},{"id":2140237,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2022-10-07T20:05:10.000Z","date":"2022-10-06","kind":"exercise","acquired":false,"shares":16231,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":8.77,"expiration_date":"2027-02-06","underlying":"Common Stock","underlying_shares":16231},"source":{"system":"sec-edgar","filing":"0001562180-22-007124","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022007124/primarydocument.xml","form_type":"4"}},{"id":2140236,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-10-07T20:05:10.000Z","date":"2022-10-06","kind":"sale","acquired":false,"shares":16231,"price":25.2916,"value":410507.9596,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person.   Following the sales reported in this Form 4, the Reporting Person has a total of 674,528 options to purchase shares of common stock that are vested and immediately exercisable and a total of 485,001 options to purchase shares of common stock that have not yet vested."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale prices ranged from $25.1500 to $25.4350."}],"balance_after":17659,"source":{"system":"sec-edgar","filing":"0001562180-22-007124","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022007124/primarydocument.xml","form_type":"4"}},{"id":2140235,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-10-07T20:05:10.000Z","date":"2022-10-06","kind":"exercise","acquired":true,"shares":16231,"price":8.77,"value":142345.87,"ownership":{"direct":true},"balance_after":33890,"source":{"system":"sec-edgar","filing":"0001562180-22-007124","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022007124/primarydocument.xml","form_type":"4"}},{"id":2143777,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2022-10-04T21:49:19.000Z","date":"2022-10-04","kind":"exercise","acquired":false,"shares":1280,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":8.77,"expiration_date":"2027-02-06","underlying":"Common Stock","underlying_shares":1280},"source":{"system":"sec-edgar","filing":"0001562180-22-007012","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022007012/primarydocument.xml","form_type":"4"}},{"id":2143776,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2022-10-04T21:49:19.000Z","date":"2022-10-03","kind":"exercise","acquired":false,"shares":2883,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":8.77,"expiration_date":"2027-02-06","underlying":"Common Stock","underlying_shares":2883},"source":{"system":"sec-edgar","filing":"0001562180-22-007012","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022007012/primarydocument.xml","form_type":"4"}},{"id":2143775,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2022-10-04T21:49:19.000Z","date":"2022-09-30","kind":"exercise","acquired":false,"shares":29606,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":8.77,"expiration_date":"2027-02-06","underlying":"Common Stock","underlying_shares":29606},"source":{"system":"sec-edgar","filing":"0001562180-22-007012","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022007012/primarydocument.xml","form_type":"4"}},{"id":2143774,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-10-04T21:49:19.000Z","date":"2022-10-04","kind":"sale","acquired":false,"shares":1280,"price":25.0206,"value":32026.368,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 690,759 options to purchase shares of common stock that are vested and immediately exercisable and a total of 485,001 options to purchase shares of common stock that have not yet vested."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The sale prices ranged from $25.00 to $25.03."}],"balance_after":17659,"source":{"system":"sec-edgar","filing":"0001562180-22-007012","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022007012/primarydocument.xml","form_type":"4"}},{"id":2143773,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-10-04T21:49:19.000Z","date":"2022-10-04","kind":"exercise","acquired":true,"shares":1280,"price":8.77,"value":11225.6,"ownership":{"direct":true},"balance_after":18939,"source":{"system":"sec-edgar","filing":"0001562180-22-007012","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022007012/primarydocument.xml","form_type":"4"}},{"id":2143772,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-10-04T21:49:19.000Z","date":"2022-10-03","kind":"sale","acquired":false,"shares":2883,"price":25.011,"value":72106.713,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 690,759 options to purchase shares of common stock that are vested and immediately exercisable and a total of 485,001 options to purchase shares of common stock that have not yet vested."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The sale prices ranged from $25.00 to $25.03."}],"balance_after":17659,"source":{"system":"sec-edgar","filing":"0001562180-22-007012","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022007012/primarydocument.xml","form_type":"4"}},{"id":2143771,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-10-04T21:49:19.000Z","date":"2022-10-03","kind":"exercise","acquired":true,"shares":2883,"price":8.77,"value":25283.91,"ownership":{"direct":true},"balance_after":20542,"source":{"system":"sec-edgar","filing":"0001562180-22-007012","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022007012/primarydocument.xml","form_type":"4"}},{"id":2143770,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-10-04T21:49:19.000Z","date":"2022-09-30","kind":"sale","acquired":false,"shares":29606,"price":25.0205,"value":740756.923,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 690,759 options to purchase shares of common stock that are vested and immediately exercisable and a total of 485,001 options to purchase shares of common stock that have not yet vested."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale prices ranged from $25.00 to $25.15."}],"balance_after":17659,"source":{"system":"sec-edgar","filing":"0001562180-22-007012","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022007012/primarydocument.xml","form_type":"4"}},{"id":2143769,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-10-04T21:49:19.000Z","date":"2022-09-30","kind":"exercise","acquired":true,"shares":29606,"price":8.77,"value":259644.62,"ownership":{"direct":true},"balance_after":47265,"source":{"system":"sec-edgar","filing":"0001562180-22-007012","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022007012/primarydocument.xml","form_type":"4"}},{"id":2201278,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2022-07-27T22:42:22.000Z","date":"2022-07-25","kind":"exercise","acquired":false,"shares":11838,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option vests periodically upon the Issuer achieving certain milestones."}],"balance_after":0,"derivative":{"exercise_price":6.38,"expiration_date":"2029-02-06","underlying":"Common Stock","underlying_shares":11838},"source":{"system":"sec-edgar","filing":"0001562180-22-005761","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022005761/primarydocument.xml","form_type":"4"}},{"id":2201277,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2022-07-27T22:42:22.000Z","date":"2022-07-25","kind":"exercise","acquired":false,"shares":19764,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option vests in 48 successive equal monthly installments measured from 02/06/2019."}],"balance_after":0,"derivative":{"exercise_price":6.38,"expiration_date":"2029-02-06","underlying":"Common Stock","underlying_shares":19764},"source":{"system":"sec-edgar","filing":"0001562180-22-005761","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022005761/primarydocument.xml","form_type":"4"}},{"id":2201276,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-07-27T22:42:22.000Z","date":"2022-07-25","kind":"sale","acquired":false,"shares":11838,"price":21.0554,"value":249253.8252,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 670,466 options to purchase shares of common stock that are vested and immediately exercisable and a total of 539,063 options to purchase shares of common stock that have not yet vested."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale prices ranged from $21.00 to $21.16."}],"balance_after":17659,"source":{"system":"sec-edgar","filing":"0001562180-22-005761","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022005761/primarydocument.xml","form_type":"4"}},{"id":2201275,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-07-27T22:42:22.000Z","date":"2022-07-25","kind":"exercise","acquired":true,"shares":11838,"price":6.38,"value":75526.44,"ownership":{"direct":true},"balance_after":29497,"source":{"system":"sec-edgar","filing":"0001562180-22-005761","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022005761/primarydocument.xml","form_type":"4"}},{"id":2201274,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-07-27T22:42:22.000Z","date":"2022-07-25","kind":"sale","acquired":false,"shares":19764,"price":21.0554,"value":416138.9256,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 670,466 options to purchase shares of common stock that are vested and immediately exercisable and a total of 539,063 options to purchase shares of common stock that have not yet vested."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale prices ranged from $21.00 to $21.16."}],"balance_after":17659,"source":{"system":"sec-edgar","filing":"0001562180-22-005761","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022005761/primarydocument.xml","form_type":"4"}},{"id":2201273,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-07-27T22:42:22.000Z","date":"2022-07-25","kind":"exercise","acquired":true,"shares":19764,"price":6.38,"value":126094.32,"ownership":{"direct":true},"balance_after":37423,"source":{"system":"sec-edgar","filing":"0001562180-22-005761","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022005761/primarydocument.xml","form_type":"4"}},{"id":2209384,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"common stock","published_at":"2022-07-11T16:51:10.000Z","date":"2022-07-07","kind":"sale","acquired":false,"shares":1100,"price":6.55,"value":7205.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000891293-22-000036","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000036/primary_doc.xml","form_type":"4"}},{"id":2209383,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"common stock","published_at":"2022-07-11T16:51:10.000Z","date":"2022-07-07","kind":"sale","acquired":false,"shares":400,"price":6.54,"value":2616.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person."}],"balance_after":1100,"source":{"system":"sec-edgar","filing":"0000891293-22-000036","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000036/primary_doc.xml","form_type":"4"}},{"id":2209382,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"common stock","published_at":"2022-07-11T16:51:10.000Z","date":"2022-07-07","kind":"sale","acquired":false,"shares":400,"price":6.53,"value":2612.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person."}],"balance_after":1500,"source":{"system":"sec-edgar","filing":"0000891293-22-000036","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000036/primary_doc.xml","form_type":"4"}},{"id":2209381,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"common stock","published_at":"2022-07-11T16:51:10.000Z","date":"2022-07-07","kind":"sale","acquired":false,"shares":3321,"price":6.52,"value":21652.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person."}],"balance_after":1900,"source":{"system":"sec-edgar","filing":"0000891293-22-000036","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000036/primary_doc.xml","form_type":"4"}},{"id":2209380,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"common stock","published_at":"2022-07-11T16:51:10.000Z","date":"2022-07-07","kind":"sale","acquired":false,"shares":5900,"price":6.51,"value":38409.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person."}],"balance_after":5221,"source":{"system":"sec-edgar","filing":"0000891293-22-000036","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000036/primary_doc.xml","form_type":"4"}},{"id":2209379,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"common stock","published_at":"2022-07-11T16:51:10.000Z","date":"2022-07-07","kind":"sale","acquired":false,"shares":9000,"price":6.5,"value":58500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person."}],"balance_after":11121,"source":{"system":"sec-edgar","filing":"0000891293-22-000036","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000036/primary_doc.xml","form_type":"4"}},{"id":2209704,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2022-07-08T21:51:10.000Z","date":"2022-07-07","kind":"exercise","acquired":false,"shares":100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option vests periodically upon the Issuer achieving certain milestones."}],"balance_after":0,"derivative":{"exercise_price":6.38,"expiration_date":"2029-02-06","underlying":"Common Stock","underlying_shares":100},"source":{"system":"sec-edgar","filing":"0001562180-22-005637","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022005637/primarydocument.xml","form_type":"4"}},{"id":2209703,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2022-07-08T21:51:10.000Z","date":"2022-07-06","kind":"exercise","acquired":false,"shares":15009,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option vests periodically upon the Issuer achieving certain milestones."}],"balance_after":0,"derivative":{"exercise_price":6.38,"expiration_date":"2029-02-06","underlying":"Common Stock","underlying_shares":15009},"source":{"system":"sec-edgar","filing":"0001562180-22-005637","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022005637/primarydocument.xml","form_type":"4"}},{"id":2209702,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-07-08T21:51:10.000Z","date":"2022-07-07","kind":"sale","acquired":false,"shares":100,"price":21,"value":2100.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 702,068 options to purchase shares of common stock that are vested and immediately exercisable and a total of 554,172 options to purchase shares of common stock that have not yet vested."}],"balance_after":17659,"source":{"system":"sec-edgar","filing":"0001562180-22-005637","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022005637/primarydocument.xml","form_type":"4"}},{"id":2209701,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-07-08T21:51:10.000Z","date":"2022-07-07","kind":"exercise","acquired":true,"shares":100,"price":6.38,"value":638.0,"ownership":{"direct":true},"balance_after":17759,"source":{"system":"sec-edgar","filing":"0001562180-22-005637","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022005637/primarydocument.xml","form_type":"4"}},{"id":2209700,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-07-08T21:51:10.000Z","date":"2022-07-06","kind":"sale","acquired":false,"shares":15009,"price":21.0745,"value":316307.1705,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 702,068 options to purchase shares of common stock that are vested and immediately exercisable and a total of 554,172 options to purchase shares of common stock that have not yet vested."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale prices ranged from $21.00 to $21.25."}],"balance_after":17659,"source":{"system":"sec-edgar","filing":"0001562180-22-005637","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022005637/primarydocument.xml","form_type":"4"}},{"id":2209699,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-07-08T21:51:10.000Z","date":"2022-07-06","kind":"exercise","acquired":true,"shares":15009,"price":6.38,"value":95757.42,"ownership":{"direct":true},"balance_after":32668,"source":{"system":"sec-edgar","filing":"0001562180-22-005637","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022005637/primarydocument.xml","form_type":"4"}},{"id":2211020,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-07-07T17:02:20.000Z","date":"2022-07-05","kind":"exercise","acquired":false,"shares":91500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares underlying the option were fully vested on May 16, 2020, the date that is twelve months after the date of grant."}],"balance_after":28500,"derivative":{"exercise_price":0.8411,"expiration_date":"2029-05-16","underlying":"Common Stock","underlying_shares":91500},"source":{"system":"sec-edgar","filing":"0000891293-22-000035","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000035/primary_doc.xml","form_type":"4"}},{"id":2211019,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"common stock","published_at":"2022-07-07T17:02:20.000Z","date":"2022-07-05","kind":"sale","acquired":false,"shares":3331,"price":6.2255,"value":20737.1405,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $ 6.21 to $ 6.25. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."}],"balance_after":20121,"source":{"system":"sec-edgar","filing":"0000891293-22-000035","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000035/primary_doc.xml","form_type":"4"}},{"id":2211018,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"common stock","published_at":"2022-07-07T17:02:20.000Z","date":"2022-07-05","kind":"sale","acquired":false,"shares":27506,"price":6.1403,"value":168895.0918,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $ 6.11 to $ 6.20. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."}],"balance_after":23452,"source":{"system":"sec-edgar","filing":"0000891293-22-000035","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000035/primary_doc.xml","form_type":"4"}},{"id":2211017,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"common stock","published_at":"2022-07-07T17:02:20.000Z","date":"2022-07-05","kind":"sale","acquired":false,"shares":51963,"price":6.0512,"value":314438.5056,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $ 6.00 to $ 6.10. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."}],"balance_after":50958,"source":{"system":"sec-edgar","filing":"0000891293-22-000035","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000035/primary_doc.xml","form_type":"4"}},{"id":2211016,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"common stock","published_at":"2022-07-07T17:02:20.000Z","date":"2022-07-05","kind":"sale","acquired":false,"shares":8700,"price":5.9766,"value":51996.42,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $ 5.95 to $ 5.99. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."}],"balance_after":102921,"source":{"system":"sec-edgar","filing":"0000891293-22-000035","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000035/primary_doc.xml","form_type":"4"}},{"id":2211015,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"common stock","published_at":"2022-07-07T17:02:20.000Z","date":"2022-07-05","kind":"exercise","acquired":true,"shares":91500,"price":0.8411,"value":76960.65,"ownership":{"direct":true},"balance_after":111621,"source":{"system":"sec-edgar","filing":"0000891293-22-000035","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000035/primary_doc.xml","form_type":"4"}},{"id":2338460,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-03-11T19:43:57.000Z","date":"2022-03-09","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option vests on the first to occur of (i) the date that is twelve months after the date of grant, and (ii) immediately prior to the first annual meeting of the Company's stockholders in 2023 at which one or more members of the Company's Board of Directors are to be elected, subject to the Reporting Person's continued service through such date or event."}],"balance_after":80000,"derivative":{"exercise_price":4.49,"expiration_date":"2032-03-09","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0000899243-22-010776","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089924322010776/doc4.xml","form_type":"4"}},{"id":2413100,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2022-02-03T22:33:11.000Z","date":"2022-02-02","kind":"grant","acquired":true,"shares":325000,"price":15.79,"value":5131750.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The securities awarded on 02/02/2022 were in the form of stock options issued pursuant to the Syndax Pharmaceuticals, Inc. 2015 Omnibus Incentive Plan. Options to purchase 245,000 shares of common stock shall vest in 48 successive equal monthly installments measured from 02/02/2022. Options to purchase 80,000 shares of common stock shall vest periodically upon the Issuer achieving certain milestones."}],"balance_after":325000,"derivative":{"exercise_price":15.79,"expiration_date":"2032-02-02","underlying":"Common Stock","underlying_shares":325000},"source":{"system":"sec-edgar","filing":"0001562180-22-001081","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022001081/primarydocument.xml","form_type":"4"}},{"id":2463592,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Stock Options (Right to buy)","published_at":"2021-12-20T23:44:33.000Z","date":"2021-12-20","kind":"exercise","acquired":false,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":6.38,"expiration_date":"2029-02-06","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001562180-21-007809","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218021007809/primarydocument.xml","form_type":"4"}},{"id":2463591,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Stock Options (Right to buy)","published_at":"2021-12-20T23:44:33.000Z","date":"2021-12-20","kind":"exercise","acquired":false,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":8.77,"expiration_date":"2027-02-06","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001562180-21-007809","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218021007809/primarydocument.xml","form_type":"4"}},{"id":2463590,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Stock Options (Right to buy)","published_at":"2021-12-20T23:44:33.000Z","date":"2021-12-17","kind":"exercise","acquired":false,"shares":1676,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":6.38,"expiration_date":"2029-02-06","underlying":"Common Stock","underlying_shares":1676},"source":{"system":"sec-edgar","filing":"0001562180-21-007809","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218021007809/primarydocument.xml","form_type":"4"}},{"id":2463589,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Stock Options (Right to buy)","published_at":"2021-12-20T23:44:33.000Z","date":"2021-12-16","kind":"exercise","acquired":false,"shares":22715,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":6.38,"expiration_date":"2029-02-06","underlying":"Common Stock","underlying_shares":22715},"source":{"system":"sec-edgar","filing":"0001562180-21-007809","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218021007809/primarydocument.xml","form_type":"4"}},{"id":2463588,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Common Stock","published_at":"2021-12-20T23:44:33.000Z","date":"2021-12-20","kind":"sale","acquired":false,"shares":45000,"price":20.288,"value":912960.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 596,031 options to purchase shares of common stock that are vested and immediately exercisable and a total of 335,209 options to purchase shares of common stock that have not yet vested."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The sale prices ranged from $19.17 to $21.01"}],"balance_after":17659,"source":{"system":"sec-edgar","filing":"0001562180-21-007809","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218021007809/primarydocument.xml","form_type":"4"}},{"id":2463587,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Common Stock","published_at":"2021-12-20T23:44:33.000Z","date":"2021-12-20","kind":"exercise","acquired":true,"shares":45000,"price":8.77,"value":394650.0,"ownership":{"direct":true},"balance_after":62659,"source":{"system":"sec-edgar","filing":"0001562180-21-007809","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218021007809/primarydocument.xml","form_type":"4"}},{"id":2463586,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Common Stock","published_at":"2021-12-20T23:44:33.000Z","date":"2021-12-20","kind":"sale","acquired":false,"shares":16000,"price":20.288,"value":324608.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 596,031 options to purchase shares of common stock that are vested and immediately exercisable and a total of 335,209 options to purchase shares of common stock that have not yet vested."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The sale prices ranged from $19.17 to $21.01"}],"balance_after":17659,"source":{"system":"sec-edgar","filing":"0001562180-21-007809","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218021007809/primarydocument.xml","form_type":"4"}},{"id":2463585,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Common Stock","published_at":"2021-12-20T23:44:33.000Z","date":"2021-12-20","kind":"exercise","acquired":true,"shares":16000,"price":6.38,"value":102080.0,"ownership":{"direct":true},"balance_after":33659,"source":{"system":"sec-edgar","filing":"0001562180-21-007809","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218021007809/primarydocument.xml","form_type":"4"}},{"id":2463584,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Common Stock","published_at":"2021-12-20T23:44:33.000Z","date":"2021-12-17","kind":"sale","acquired":false,"shares":1676,"price":19.0198,"value":31877.1848,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 596,031 options to purchase shares of common stock that are vested and immediately exercisable and a total of 335,209 options to purchase shares of common stock that have not yet vested."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The sale prices ranged from $19.00 to $19.06."}],"balance_after":17659,"source":{"system":"sec-edgar","filing":"0001562180-21-007809","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218021007809/primarydocument.xml","form_type":"4"}},{"id":2463583,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Common Stock","published_at":"2021-12-20T23:44:33.000Z","date":"2021-12-17","kind":"exercise","acquired":true,"shares":1676,"price":6.38,"value":10692.88,"ownership":{"direct":true},"balance_after":19335,"source":{"system":"sec-edgar","filing":"0001562180-21-007809","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218021007809/primarydocument.xml","form_type":"4"}},{"id":2463582,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Common Stock","published_at":"2021-12-20T23:44:33.000Z","date":"2021-12-16","kind":"sale","acquired":false,"shares":22715,"price":19.0799,"value":433399.9285,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 596,031 options to purchase shares of common stock that are vested and immediately exercisable and a total of 335,209 options to purchase shares of common stock that have not yet vested."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale prices ranged from $19.00 to $19.30."}],"balance_after":17659,"source":{"system":"sec-edgar","filing":"0001562180-21-007809","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218021007809/primarydocument.xml","form_type":"4"}},{"id":2463581,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Common Stock","published_at":"2021-12-20T23:44:33.000Z","date":"2021-12-16","kind":"exercise","acquired":true,"shares":22715,"price":6.38,"value":144921.7,"ownership":{"direct":true},"balance_after":40374,"source":{"system":"sec-edgar","filing":"0001562180-21-007809","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218021007809/primarydocument.xml","form_type":"4"}},{"id":2471299,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Stock Options (Right to buy)","published_at":"2021-12-15T22:35:28.000Z","date":"2021-12-13","kind":"exercise","acquired":false,"shares":34564,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":6.38,"expiration_date":"2029-02-06","underlying":"Common Stock","underlying_shares":34564},"source":{"system":"sec-edgar","filing":"0001562180-21-007710","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218021007710/primarydocument.xml","form_type":"4"}},{"id":2471298,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Stock Options (Right to buy)","published_at":"2021-12-15T22:35:28.000Z","date":"2021-12-13","kind":"exercise","acquired":false,"shares":2045,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":7.2,"expiration_date":"2025-06-01","underlying":"Common Stock","underlying_shares":2045},"source":{"system":"sec-edgar","filing":"0001562180-21-007710","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218021007710/primarydocument.xml","form_type":"4"}},{"id":2471297,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Common Stock","published_at":"2021-12-15T22:35:28.000Z","date":"2021-12-13","kind":"sale","acquired":false,"shares":34564,"price":19.0532,"value":658554.8048,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person.  Following the sales reported in this Form 4, the Reporting Person has a total of 681,422 options to purchase shares of common stock that are vested and immediately exercisable and a total of 335,209 options to purchase shares of common stock that have not yet vested."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale prices ranged from $19.00 to $19.49."}],"balance_after":17659,"source":{"system":"sec-edgar","filing":"0001562180-21-007710","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218021007710/primarydocument.xml","form_type":"4"}},{"id":2471296,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Common Stock","published_at":"2021-12-15T22:35:28.000Z","date":"2021-12-13","kind":"exercise","acquired":true,"shares":34564,"price":6.38,"value":220518.32,"ownership":{"direct":true},"balance_after":52223,"source":{"system":"sec-edgar","filing":"0001562180-21-007710","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218021007710/primarydocument.xml","form_type":"4"}}],"next_cursor":"2021-12-15T22:35:28.000000Z,2471296"}